Good evening good people,
Well, that was some kind of CC.
5 Key Takeaways:
1.While COVID-19 and its many new variants is spiraling out of control in Eurozone, South America and Asia, CYDY parts ways with its Chief Science Officer who was in charge of getting the BLA across the finish line.
2. We learn that 28 more critical patients in the Philippines will be given LL and that 100k vials are being prepped for delivery pending authorization/approval/Duarte sleeping at a Holiday Inn Express
3. We were told/not told that CYDY has been "reached our to" by BP but they "can not comment" on said reach outs.
4. $25mm convertible raise WITHOUT warrants attached was strictly for "production".
5. Exclusive supply/distribution deal with Biomm S.A signed for Brazil, where people are currently dropping dead in the streets in Manaus.
My hunch earlier was MHRA given their new Innovation Passport program was on deck and that Mahboob may have been dispatched to London to expedite that. Now we learn Mahboob was gone as of Monday which is AFTER the $25mm convertible raise WITHOUT warrants attached and *while* the company received news of the additional 28 patients in the Philippines and the exclusive licensing deal in Brazil.
The MOST interesting bit of information communicated to me on this call was actually not relayed in any of the many words spoken nor any of the data delivered. Instead, it was the tone and levity of one particular individual's voice and that person's overall demeanor. When I connect numbers 3 and 4 above with the sheer happiness and relief sounded in our General Counsel's voice I can only come to one disturbing conclusion:
Management has most likely received a very, VERY compelling buyout offer from a major BP.
Ladies and gentlemen, for a company the size of CYDY prepping and releasing PRs daily, negotiating international exclusive deals, moving on its most recent executive hire in a CSO role and finalizing various MSAs with Philippine partners and local hospitals... well, your General Counsel should NOT, I repeat NOT sound happy. She should NOT be lightheartedly smiling while taking and relaying questions. LAWYERS are not normally HAPPY people- at work or away from work, because they are ALWAYS working! ESPECIALLY at a company like CYDY.
Unless of course, suddenly they learn that
A. They are about to be generationally RICH RICH RICH
B. They will no longer have to come to work while simultaneously becoming RICH RICH RICH.
Btw, a compelling buyout offer from a major BP would ALSO NEGATE the need for the continued employment and salary expense of the recently hired CSO. I'm quite certain Mahboob's employment contract was back-end loaded with deferred equity option grants ONCE certain FDA approvals and commercialization milestones were met. A buyout by a major BP cancels each of those plus his job role.
My money is on Pfizer, Amgen or Merck. The latter 2 being relatively too quiet on all things COVID-19 and Amgen being a leader in the MAB space/race. For the addressable market fans out there, consider that Brazil (pop. 212mm) and the Philippines (pop.110mm) combined have nearly the exact sized population of the USA (pop. 331mm). Keep in mind that neither Brazil nor the Philippines have access to similar amounts of vaccines as the USA nor the capacity to do wide reaching vaccination of their populations without SIGNIFICANT cost.
Stay safe
TSOV
Well, that was some kind of CC.
5 Key Takeaways:
1.While COVID-19 and its many new variants is spiraling out of control in Eurozone, South America and Asia, CYDY parts ways with its Chief Science Officer who was in charge of getting the BLA across the finish line.
2. We learn that 28 more critical patients in the Philippines will be given LL and that 100k vials are being prepped for delivery pending authorization/approval/Duarte sleeping at a Holiday Inn Express
3. We were told/not told that CYDY has been "reached our to" by BP but they "can not comment" on said reach outs.
4. $25mm convertible raise WITHOUT warrants attached was strictly for "production".
5. Exclusive supply/distribution deal with Biomm S.A signed for Brazil, where people are currently dropping dead in the streets in Manaus.
My hunch earlier was MHRA given their new Innovation Passport program was on deck and that Mahboob may have been dispatched to London to expedite that. Now we learn Mahboob was gone as of Monday which is AFTER the $25mm convertible raise WITHOUT warrants attached and *while* the company received news of the additional 28 patients in the Philippines and the exclusive licensing deal in Brazil.
The MOST interesting bit of information communicated to me on this call was actually not relayed in any of the many words spoken nor any of the data delivered. Instead, it was the tone and levity of one particular individual's voice and that person's overall demeanor. When I connect numbers 3 and 4 above with the sheer happiness and relief sounded in our General Counsel's voice I can only come to one disturbing conclusion:
Management has most likely received a very, VERY compelling buyout offer from a major BP.
Ladies and gentlemen, for a company the size of CYDY prepping and releasing PRs daily, negotiating international exclusive deals, moving on its most recent executive hire in a CSO role and finalizing various MSAs with Philippine partners and local hospitals... well, your General Counsel should NOT, I repeat NOT sound happy. She should NOT be lightheartedly smiling while taking and relaying questions. LAWYERS are not normally HAPPY people- at work or away from work, because they are ALWAYS working! ESPECIALLY at a company like CYDY.
Unless of course, suddenly they learn that
A. They are about to be generationally RICH RICH RICH
B. They will no longer have to come to work while simultaneously becoming RICH RICH RICH.
Btw, a compelling buyout offer from a major BP would ALSO NEGATE the need for the continued employment and salary expense of the recently hired CSO. I'm quite certain Mahboob's employment contract was back-end loaded with deferred equity option grants ONCE certain FDA approvals and commercialization milestones were met. A buyout by a major BP cancels each of those plus his job role.
My money is on Pfizer, Amgen or Merck. The latter 2 being relatively too quiet on all things COVID-19 and Amgen being a leader in the MAB space/race. For the addressable market fans out there, consider that Brazil (pop. 212mm) and the Philippines (pop.110mm) combined have nearly the exact sized population of the USA (pop. 331mm). Keep in mind that neither Brazil nor the Philippines have access to similar amounts of vaccines as the USA nor the capacity to do wide reaching vaccination of their populations without SIGNIFICANT cost.
Stay safe
TSOV
20
